{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:41:24Z","timestamp":1792442484565,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.it.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:31:25Z","timestamp":1784183485000},"page":"889-906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional heterogeneity of macrophages in distinct niches of hepatocellular carcinoma"],"prefix":"10.1016","volume":"47","author":[{"given":"Jinglong","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Comps-Agrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon J.","family":"Turley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-8929","authenticated-orcid":false,"given":"Wenxian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2026.06.009_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.it.2026.06.009_bb0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.it.2026.06.009_bb0015","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.immuni.2022.08.002","article-title":"Liver macrophages in health and disease","volume":"55","author":"Guilliams","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Perdiguero","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.06.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf4238","article-title":"Specification of tissue-resident macrophages during organogenesis","volume":"353","author":"Mass","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.it.2026.06.009_bb0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ph11040137","article-title":"Iron regulation: macrophages in control","volume":"11","author":"Sukhbaatar","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.it.2026.06.009_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq5202","article-title":"Kupffer cell\u2013like syncytia replenish resident macrophage function in the fibrotic liver","volume":"381","author":"Peiseler","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.it.2026.06.009_bb0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0045","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s41418-021-00797-w","article-title":"Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice","volume":"28","author":"Jiang","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.it.2026.06.009_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv2106","article-title":"Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"17","author":"Shi","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0055","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2005.12.039","article-title":"CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens","volume":"124","author":"Helmy","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0060","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/2326-6066.CIR-25-0836","article-title":"VSIG4 restricts hepatocellular carcinoma control by suppressing tumor-specific CD8+ T-cell immunity in the tumor microenvironment","volume":"14","author":"Guo","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2026.06.009_bb0065","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2017.07.018","article-title":"A liver capsular network of monocyte-derived macrophages restricts hepatic dissemination of intraperitoneal bacteria by neutrophil recruitment","volume":"47","author":"Sierro","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0070","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.06.009_bb0075","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0080","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1866","article-title":"Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation","volume":"16","author":"Zhou","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"Ganguly","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.06.009_bb0095","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000540","article-title":"Spatial mapping of the HCC landscape identifies unique intratumoral perivascular-immune neighborhoods","volume":"8","author":"Marsh-Wakefield","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.it.2026.06.009_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.it.2026.06.009_bb0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0115","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41422-023-00831-1","article-title":"An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte\u2013tumor cell crosstalk, local immunosuppression and tumor progression","volume":"33","author":"Wu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.it.2026.06.009_bb0125","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.7150\/thno.99046","article-title":"DAB2+ macrophages support FAP+ fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer","volume":"14","author":"Long","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.it.2026.06.009_bb0130","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.it.2026.06.009_bb0135","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ccell.2024.10.012","article-title":"Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma","volume":"42","author":"Huang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","article-title":"Immune phenotypic linkage between colorectal cancer and liver metastasis","volume":"40","author":"Liu","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1158\/1078-0432.CCR-22-2041","article-title":"Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor associated SPP1+ macrophages and fibroblasts","volume":"29","author":"Sathe","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.06.009_bb0150","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1038\/s41467-025-59529-0","article-title":"SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases","volume":"16","author":"Trehan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.06.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202412740","article-title":"Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area","volume":"12","author":"Zuyin","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.it.2026.06.009_bb0160","article-title":"Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma","volume":"5","author":"Liu","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.it.2026.06.009_bb0165","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.it.2026.06.009_bb0170","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000533","article-title":"HCC spatial transcriptomic profiling reveals significant and potentially targetable cancer-endothelial interactions","volume":"8","author":"Lu","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.it.2026.06.009_bb0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.dld.2024.06.016","article-title":"The tumor microenvironment of VETC+ hepatocellular carcinoma is enriched of immunosuppressive TAMs spatially close to endothelial cells","volume":"57","author":"De Carlo","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.it.2026.06.009_bb0185","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-16-2131","article-title":"Vascular CXCR4 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma","volume":"23","author":"Xu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.06.009_bb0190","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.3390\/cancers13133253","article-title":"New angiogenic regulators produced by tams: perspective for targeting tumor angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.it.2026.06.009_bb0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0200","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer","volume":"185","author":"Ramos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13058-025-01980-4","article-title":"Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing","volume":"27","author":"Wu","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.06.009_bb0210","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.tips.2017.05.002","article-title":"Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies","volume":"38","author":"Qiu","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.it.2026.06.009_bb0215","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/0008-5472.CAN-15-0977","article-title":"Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis","volume":"76","author":"Ye","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.009_bb0220","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.32419","article-title":"Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC","volume":"76","author":"Suthen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.it.2026.06.009_bb0225","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.25572","article-title":"High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases","volume":"55","author":"Yan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.it.2026.06.009_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70137-4","article-title":"Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2\/NOX2\/autophagy axis","volume":"10","author":"Shiau","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2026.06.009_bb0235","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1172\/JCI137553","article-title":"Hypoxia-inducible factors and innate immunity in liver cancer","volume":"130","author":"Yuen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2026.06.009_bb0240","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/hep.29681","article-title":"Hypoxia-inducible factor-1\u03b1\/interleukin-1\u03b2 signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment","volume":"67","author":"Zhang","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.it.2026.06.009_bb0245","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s43018-024-00824-y","article-title":"Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma","volume":"5","author":"Qiu","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.33590\/emjhepatol\/QCRI8208","article-title":"Niche-specific reprogramming of macrophages reveals myeloid cell-centric targets during pro-senescence therapy in liver cancer","volume":"131","author":"Tsouri","year":"2025","journal-title":"EMJ Hepatol."},{"key":"10.1016\/j.it.2026.06.009_bb0255","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1172\/JCI66024","article-title":"Cancer stem cells in the development of liver cancer","volume":"123","author":"Yamashita","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2026.06.009_bb0260","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","article-title":"Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease","volume":"5","author":"Lemaitre","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0265","article-title":"Identification of a cancer stem cell-like subpopulation that promotes HCC metastasis","volume":"7","author":"Yang","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.it.2026.06.009_bb0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-024-00564-3","article-title":"Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma","volume":"8","author":"Fan","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0275","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.06.009_bb0280","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.06.009_bb0285","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.102144","article-title":"Lymphocyte function in tertiary lymphoid structures predicts hepatocellular carcinoma outcome","volume":"104","author":"Li","year":"2024","journal-title":"Lab. Investig."},{"key":"10.1016\/j.it.2026.06.009_bb0295","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0300","article-title":"Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy","volume":"6","author":"Xing","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0305","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.it.2026.06.009_bb0310","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.it.2026.06.009_bb0315","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.3390\/cancers14194821","article-title":"A novel selective Axl\/Mer\/CSF1R kinase inhibitor as a cancer immunotherapeutic agent targeting both immune and tumor cells in the tumor microenvironment","volume":"14","author":"Jeon","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.it.2026.06.009_bb0320","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2025.43.16_suppl.2606","article-title":"A phase 1b\/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: results of a phase 1 study (QRNT-008)","volume":"43","author":"Chon","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.it.2026.06.009_bb0330","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12935-022-02771-z","article-title":"Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma","volume":"22","author":"Tian","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.it.2026.06.009_bb0335","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.it.2026.06.009_bb0340","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.it.2026.06.009_bb0345","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0350","article-title":"629\u202fNeoadjuvant nivolumab combined with CCR2\/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma","volume":"10","author":"Venturini","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0355","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.06.009_bb0360","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2021-153683","article-title":"CD47-Blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.009_bb0365","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1200\/JCO.2025.43.16_suppl.6019","article-title":"An open-label, phase Ib trial of the SIRP\u03b1 inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma","volume":"43","author":"L","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0370","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0375","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1186\/s12885-023-10971-7","article-title":"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679\/ECHO-302)","volume":"23","author":"Lara","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0380","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1186\/s12885-023-11316-0","article-title":"Pembrolizumab plus epacadostat in patients with recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-669\/ECHO-304): a phase 3, randomized, open-label study","volume":"23","author":"Cho","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-023-01416-w","article-title":"Phase I\/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma","volume":"42","author":"Huynh","year":"2024","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.it.2026.06.009_bb0390","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0395","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.it.2026.06.009_bb0400","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0405","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0410","doi-asserted-by":"crossref","first-page":"89","DOI":"10.36401\/JIPO-23-4","article-title":"T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review","volume":"7","author":"Duong","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0415","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2023.41.4_suppl.578","article-title":"Tebotelimab, a PD-1\/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and\/or immunotherapy: an open-label, single-arm, phase 1\/2 dose-escalation and expansion study","volume":"41","author":"Ren","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0420","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0425","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4218","article-title":"A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma","volume":"43","author":"Humphries","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0435","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0440","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027235","article-title":"Inhibition of the CD47-SIRP\u03b1 axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data","volume":"13","author":"Son","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0450","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.it.2026.06.009_bb0455","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000413","article-title":"The fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0460","first-page":"A322","article-title":"295 first-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas","volume":"8","author":"Lakhani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0465","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.009_bb0470","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.it.2026.06.009_bb0475","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0480","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.it.2026.06.009_bb0485","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0490","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.it.2026.06.009_bb0495","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.it.2026.06.009_bb0500","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14712598.2022.2098675","article-title":"Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer","volume":"22","author":"Sewnath","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.it.2026.06.009_bb0505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00262-007-0357-5","article-title":"A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors","volume":"57","author":"Fury","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.06.009_bb0510","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.009_bb0520","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.06.009_bb0525","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/modpathol.3800436","article-title":"The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma","volume":"18","author":"Yamauchi","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.it.2026.06.009_bb0530","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jgh.16872","article-title":"Current landscape of adoptive cell therapy and challenge to develop \u201coff-the-shelf\u201d therapy for hepatocellular carcinoma","volume":"40","author":"Shin","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.it.2026.06.009_bb0535","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.009_bb0540","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.06.009_bb0545","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.it.2026.06.009_bb0550","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.009_bb0555","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg9518","article-title":"Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression","volume":"7","author":"Opzoomer","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.it.2026.06.009_bb0560","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0565","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fcell.2018.00038","article-title":"Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors","volume":"6","author":"Cassetta","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.it.2026.06.009_bb0570","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.06.009_bb0575","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.it.2026.06.009_bb0580","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ccell.2024.04.002","article-title":"A temporal perspective for tumor-associated macrophage identities and functions","volume":"42","author":"Bl\u00e9riot","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0585","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.06.009_bb0590","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.06.009_bb0595","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.06.009_bb0600","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.06.009_bb0605","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.it.2026.06.009_bb0610","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.001","article-title":"Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy","volume":"325","author":"Shobaki","year":"2020","journal-title":"J. Control. Release"}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:05:58Z","timestamp":1792440358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490626001651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1471490626001651"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2026.06.009","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional heterogeneity of macrophages in distinct niches of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}